Decreased VIP and VPAC2 receptor expression in the biological clock of the R6/2 Huntington's disease mouse

Journal of Molecular Neuroscience

Volumn 31, Issue 2, 2007, Pages 139-148

  Fahrenkrug, Jan ^a   Popovic, Natalija ^b   Georg, Birgitte ^a   Brundin, Patrik ^b   Hannibal, Jens ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Circadian rhythm; Huntington's disease; Suprachiasmatic nucleus; Vasoactive intestinal polypeptide

Indexed keywords

MESSENGER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CELL LOSS; CIRCADIAN RHYTHM; COGNITIVE DEFECT; CONTROLLED STUDY; ENDOCRINE DISEASE; GENE EXPRESSION; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPRACHIASMATIC NUCLEUS;

MUS; MUS MUSCULUS;

EID: 34248359403     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Abrahamson E. E. and Moore R. Y. (2001) Suprachiasmatic nucleus in the mouse: retinal innervation, intrinsic organization and efferent projections. Brain Res. 916, 172-191.
2. Abrahamson E. E., Leak R. K., and Moore R. Y. (2001) The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 12, 435-440.
3. Arrasate M., Mitra S., Schweitzer E. S., Segal M. R., and Finkbeiner S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810.
4. Aton S. J., Colwell C. S., Harmar A. J., Waschek J. A., and Herzog E. D. (2005) Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat. Neurosci. 8, 476-483.
5. Buijs R. M. and Kalsbeek A. (2001) Hypothalamic integration of central and peripheral clocks. Nat. Rev. Neurosci. 2, 521-526.
6. Carter R. J., Lione L. A., Humby T., Mangiarini L., Mahal A., Bates G. P., et al. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19, 3248-3257.
7. Colwell C. S., Michel S., Itri J., Rodriguez W., Tam J., Lelievre V., et al. (2003) Disrupted circadian rhythms in VIP and PHI-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R939-R949.
8. Cutler D. J., Haraura M., Reed H. E., Shen S., Sheward W. J., Morrison C. F., et al. (2003) The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro. Eur. J. Neurosci. 17, 197-204.
9. Emson P., Fahrenkrug J., and Spokes E. G. (1979) Vasoactive intestinal polypeptide (VIP): distribution in normal human brain and in Huntington's disease. Brain Res. 173, 174-178.
10. Fahrenkrug J. and Hannibal J. (1998) Pituitary adenylate cyclase activating polypeptide immunoreactivity in capsaicin-sensitive nerve fibres supplying the rat urinary tract. Neuroscience 83, 1261-1272.
11. Fahrenkrug J., Hannibal J., Honoré B., and Vorum H. (2005) Altered calmodulin response to light in the suprachiasmatic nucleus of PAC1 receptor knockout mice revealed by proteomic analysis. J. Mol. Neurosci. 25, 251-258.
12. Hannibal J. and Fahrenkrug J. (2004) Melanopsin containing retinal ganglion cells are light responsive from birth. Neuroreport 15, 2317-2320.
13. Hannibal J., Georg B., Hindersson P., and Fahrenkrug J. (2005) Light and darkness regulate melanopsin in the retinal ganglion cells of the albino Wistar rat. J. Mol. Neurosci. 27, 147-155.
14. Harmar A. J., Marston H. M., Shen S., Spratt C., West K. M., Sheward W. J., et al. (2002) The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109, 497-508.
15. Herzog E. D., Geusz M. E., Khalsa S. B. S., Straume M., and Block G. D. (1997) Circadian rhythms in mouse suprachiasmatic nucleus explants on multimicroelectrode plates. Brain Res. 757, 285-290.
16. Herzog E. D., Takahashi J. S., and Block G. D. (1998) Clock controls circadian period in isolated suprachiasmatic nucleus neurons. Nat. Neurosci. 1, 708-713.
17. Honma S., Shirakawa T., Katsuno Y., Namihira M., and Honma K.- I. (1998) Circadian periods of single suprachiasmatic neurons in rats. Neurosci. Lett. 250, 157-160.
18. Huang C. C., Faber P. W., Persichetti F., Mittal V., Vonsattel J. P., MacDonald M. E., and Gusella J. F. (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell. Mol. Genet. 24, 217-233.
19. 2 receptor. J. Neurosci. 24, 3522-3526.
20. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
21. Iannicola C., Moreno S., Oliverio S., Nardacci R., Ciofi-Luzatto A., and Piacentini M. (2000) Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J. Neurochem. 75, 830-839.
22. Itri J., Michel S., Waschek J. A., and Colwell C. S. (2004) Circadian rhythm in inhibitory synaptic transmission in the mouse suprachiasmatic nucleus. J. Neurophysiol. 92, 311-319.
23. Kalamatianos T., Kalló I., Piggins H. D., and Coen C. W. (2004) Expression of VIP and/or PACAP receptor mRNA in peptide synthesizing cells within the suprachiasmatic nucleus of the rat and in its efferent target sites. J. Comp. Neurol. 475, 19-35.
24. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., and Housman D. (1999) Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 96, 11,404-11,409.
25. Kotliarova S., Jana N. R., Sakamoto N., Kurosawa M., Miyazaki H., Nekooki M., et al. (2005) Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J. Neurochem. 93, 641-653.
26. Li S. H., Cheng A. L., Zhou H., Lam S., Rao M., Li H., and Li X. J. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell Biol. 22, 1277-1287.
27. Luthi-Carter R., Hanson S. A., Strand A. D., Bergstrom D. A., Chun W., Peters N. L., et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11, 1911-1926.
28. Luthi-Carter R., Strand A., Peters N. L., Solano S. M., Hollingsworth Z. R., Menon A. S., et al. (2000) Decreased expression of striatal signalling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 1259-1271.
29. Maat-Schieman K. L., Dorsman K. L., Smoor M. A., Siesling S., Van Duinen S. G., Vershuuren J. J., et al. (1999) Distribution of inclusions in neuronal nuclei and dystrophic neuritis in Huntington disease brain. J. Neuropathol. Exp. 58, 129-137.
30. Mangiarini L., Sathasivam K., Seller K., Cozens B., Harper A., Hetherington C., et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
31. Markianos M., Panas M., Kalfakis N., and Vassilopoulos D. (2005) Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann. Neurol. 57, 520-525.
32. Maywood E. S., Reddy A. B., Wong G. K. Y., O'Neill J. S., O'Brien J. A., McMahon D. G., et al. (2006) Synchronization and maintenance of timekeeping in suprachiasmatic circadian clock cells by neuropeptidergic signaling. Curr. Biol. 16, 599-605.
33. Mazurek M. F., Garside S., and Beal M. F. (1997) Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Ann. Neurol.41,540-547.
34. Moore R. Y., Speh J. C., and Leak R. K. (2002) Suprachiasmatic nucleus organization. Cell Tissue Res. 309, 89-98.
35. Morton A. J., Wood N. I., Hastings M. H., Hurelbrink C., Barker R. A., and Maywood E. S. (2005) Disintegration of the sleep-wake cycle and cicadian timing in Huntington's disease. J. Neurosci. 25, 157-163.
36. Nucifora F. C. Jr., Sasaki M., Peters M. F., Huang H., Cooper J. K., Yamada M., et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428.
37. Okamura H. (2004) Clock genes in cell clocks: roles, actions, and mysteries. J. Biol. Rhythms 19, 388-399.
38. Papalexi E., Persson A., Björkqvist M., Petersén Å., Woodman B., Bates G.P., et al. (2005) Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci. 22, 1541-1546.
39. Petersén Å., Gil J., Maat-Schieman L. C., Björkqvist M., Tanila H., Araújo I. M., et al. (2005) Orexin loss in Huntington's disease. Hum. Mol. Genet. 14, 39-47.
40. Quintero J. E., Kuhlman S. J., and McMahon D. G. (2006) The biological clock nucleus: a multiphasic oscillator network regulated by light. J. Neurosci. 23, 8070-8076.
41. Reed H. E., Cutler D. J., Brown T. M., Brown J., Coen C. W., and Piggins H. D. (2002) Effects of vasoactive intestinal polypeptide on neurones of the rat suprachiasmatic nuclei in vitro. J. Neuroendocrinol. 14, 639-646.
42. Reppert S. M. and Weaver D. R. (2002) Coordination of circadian timing in mammals. Nature 418, 935-941.
43. Reppert S. M. and Weaver D. R. (2001) Molecular analysis of mammalian circadian rhythms. Annu. Rev. Physiol. 63, 647-676.
44. Sadri-Vakili G., Menon A. S., Farrell L. A., Keller-McGandy C. E., Cantuti-Castelvetri I., Standaert D. G., et al. (2006) Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse. Eur. J. Neurosci. 23, 3171-3175.
45. Schaap J., Albus H., van derLeest H. T., Eilers P. H. C., Détari L., and Meijer J. H. (2003) Heterogeneity of rhythmic suprachiasmatic nucleus neurons: implications for circadian waveform and photoperiodic encoding. Proc. Natl. Acad. Sci. U. S. A. 100, 15,994-15,999.
46. Stack E. C., Kubilus J. K., Smith K., Cormier K., Del Signore S. J., Guelin E., et al. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 490, 354-370.
47. Steffan J. S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y. Z., Gohler H., et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 97, 6763-6768.
48. Taheri S., Zeitzer J. M., and Mignot E. (2002) The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu. Rev. Neurosci. 25, 283-313.
49. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G. P., and Davies S. W. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 97, 8093-8097.
50. VonSattel J. P. G. and DiFiglia M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369-384.
51. Welsh D. K., Logothetis D. E., Meister M., and Reppert S. M. (1995) Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. Neuron 14, 697-706.
52. Yamaguchi S., Isejima H., Matsuo T., Okura R., Yagita K., Kobayashi M., and Okamura H. (2003) Synchronization of cellular clocks in the suprachiasmatic nucleus. Science 302, 1408-1412.
53. Zucker B., Luthi-Carter R., Kama J. A., Dunah A. W., Stern E. A., Fox J. H., et al. (2005) Transcriptional dysregulation in striatal projections and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol. Genet. 14, 179-189.